Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS Medicinal Chemistry Letters January 9, 2025 DOI: 10.1021/acsmedchemlett.4c00581 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression PTSD Serotonin |
| Citations | 7 |
| Key points | Novel 3-pyrrolidineindole derivatives act as serotonergic psychedelic agents with potential to treat depression, post-traumatic stress disorder, and psychosis. |
Abstract
Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.
Citations in the library
Cited by 5
- Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders. ACS Medicinal Chemistry Letters January 23, 2025
- Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders. ACS Medicinal Chemistry Letters February 13, 2025
- Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders. ACS Medicinal Chemistry Letters March 13, 2025
- Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders. ACS Medicinal Chemistry Letters February 11, 2025
- Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses. ACS Medicinal Chemistry Letters January 23, 2025
Cites 4
- Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants Chemical Reviews November 30, 2023
- Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Research 2025
- 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review. ACS Pharmacology & Translational Science June 14, 2024
- Psychedelic therapy in depression and substance use disorders European Journal of Neuroscience May 21, 2024